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without prophylactic DLI (38.0% vs 11.8%,P¼0.001). Sex, age,
conditioning regimen (dosage of ATG), number of HLA mis-
matched or the number of stem cells infused were not the
factors affecting OS, DFS and relapse. Multivariate analysis
showed that the signiﬁcant factors associated with higher OS
were the use of prophylactic DLI, the disease type of AML and
occurrence of chronic GVHD.
Conclusions: Haploidentical allo-HSCT can cure a signiﬁcant
proportion of refractory/relapsed acute leukemia patients.
Prophylactic DLI can reduce relapse and increase survival; for
patients with refractory/relapsed ALL, other post-transplant
therapy should be explored.
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CMV disease in patients undergoing allogeneic HCT is
a major source of morbidity and mortality. CMV PCR allows
for earlier detection of viremia and preemptive anti-viral
therapy. A recent study by Milano et al. (Blood 2011) has
reported the efﬁcacy of the use of intensive CMV prophylaxis
in umbilical cord blood recipients. In this case series (table
below), we describe 3 patients in whom active CMV disease
was detected in the context of a viral load which ﬂuctuatedTable
Patient 1 Patient 2 Patient 3
Age/Sex 11/M 4/M 10/M
Underlying
Diagnosis
SAA with
secondary M7 AML
High risk
pre-B cell ALL
Relapsed
pre-B cell ALL
Donor
Source
Double umbilical
cord (dUCB)
9/10 matched
unrelated donor
dUCB
GVHD None Grade IV skin,
gut, and liver
GVHD
Grade III skin
and gut GVHD
CMV viral
load at
biopsy/
Range
<150 copies/ml
Not detected - <150
<150 copies/ml
Not detected -
<150
#1- 400
copies/ml, #2-
not detected
Not detected -
11,200
Disease Day +42
Esophagoduodenal
endoscopy: Gastritis
with CMV inclusions
and CMV positive
immunohistochemical
stain
Day +285
Cholecystectomy:
Perforated
chronic
cholecystitis
with hemobilia,
CMV PCR pos
Day +162
Left endoscopic
sphenoidotomy:
Chronic
inﬂammation
with shell vial
CMV positivity
Day +286 Lung
biopsy: CMV
PCR pos
Outcome Symptoms of gastritis
resolved
Gradual but
complete
recovery after
stabilization in
the
ICU
Symptoms
improved,
Follow up CT
scans showed
improvementbetween very low level viremia (<150 copies/ml) and
undetectable. The patients (3 males, ages 4-11), all received
high risk transplants (2 double cord, 1 9/10 URD) for
advanced leukemias. All three received myeloablative doses
of total body irradiation and cyclophosphamide and the two
cord blood recipients received ﬂudarabine additionally. All
patients were CMV sero-positive while their donors were
CMV sero-negative. They had symptomatic biopsy-proven
CMV disease in various locations including the stomach,
gallbladder, sinuses and lung. They were treated with intra-
venous ganciclovir and Cytogam induction and two transi-
tioned to foscarnet due to myelosuppression. All three
recovered from their symptomatic disease, although they
continued to have ﬂuctuating positivity of their serum CMV
PCR. This experience at a single institution in the last year
suggests that although CMV PCR has reduced the need for
prophylactic ganciclovir in patients undergoing allogeneic
HCT, active infection can develop in high risk patients even
with very low level of viremia. Therefore, an intensive
prophylactic strategy and treatment of any level of viremia,
along with a high index of suspicion for CMV disease is
required in high risk patients. Additionally, tissue diagnosis,
especially with unusual organ involvement such as gall-
bladder in our patient, should be obtained when possible.408
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Risk Acute Myeloid Leukemia and Myelodysplastic
Syndrome
Alzbeta Zavrelova, Jakub Radocha, Miriam Lanska, Pavel Zak.
Faculty Hospital Hradec Kralove, IV. department of internal
medicine - hematology, Czech Republic
Aim: To evaluate this strategy in high risk acute myeloid
leukemia (AML) and myelodysplastic syndrome (MDS).
We treated 17 patients with AML or MDS. This cohort
consisted of nine patients who did not reach complete
remission, 5 patients who reached complete remission but
remainedwith high burden of residual disease and 3 patients
up front transplanted for myelodysplatic syndrome with
high blast count. Median age was 54 years (32-65years).
Median count of blasts in bone marrow before sequential
transplantationwas 9% (1-76%). 6 patients were transplanted
with HLA identical sibling, 8 patients were transplanted with
matched unrelated donor (10/10) and 3 patients had unre-
lated donor with one mismatch (9/10). Flag-Ida chemo-
therapy (CHT) (n¼4), 3+7 CHT (n¼7) or CHT based on
monotherapy with Cytarabin was used as a cytoreduction.
Between cytoreductive CHT and preparative regimen was
instituted rest period with median of 5 days (2-14 days).
After these days of rest preparative regimen consisted of
Fludarabin/Busulfan was initiated. Total dose o Busulfan was
8mg/kg n¼6), 12mg/kg(n¼6) nad 16mg/kg (n¼5). Thymo-
globulin (total dose 7,5mg/kg) was used in case of unrelated
donor in days -3 to -1.
Results: Estimated overall survival at 2 years was 67,6%.
Whole regimen was tolerated very well even with the
highest dose of Busulfan. Transplant related mortality at 100
days was 6% (1 patient with insuﬁtient engraftment died due
to infection). 5 patients relapsed after transplantation, 1
patient progressed after transplantation. From these patients
just 1 patient did not die due to relapse and was succesfully
rescued with chemotherapy and donor lymphocyte infusion.
Conclusion: Sequential transplantation is our method of
choice in high risk AML and MDS. We demonstrate very low
transplant related mortality and promising long term
survival of this cohort of high risk patients.
